RxDoctor Payments Data

Russell Drozdiak, MD

Family Medicine · Clymer, PANPI 1144294588

Payments from drug & device makers

$518in general payments, 2019–2025

Across 33 payments — averaging $15.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$80
  • Lilly USA, LLC$70
  • Amgen$59
  • Novo Nordisk$52
  • Pfizer$45
  • Johnson & Johnson$41
  • plus $173 from 8 others

What the payments were for

  • Food & beverage$518100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Abbott4$80
Lilly USA, LLC4$70
Amgen4$59
Novo Nordisk3$52
Pfizer3$45
Johnson & Johnson3$41
Amarin Pharma, Inc.2$34
Dexcom, Inc.2$34
Boehringer Ingelheim2$27
Sanofi Pasteur Inc.2$26
GSK1$15
Exact Sciences1$13
Merck1$12
Nalpropion Pharmaceuticals LLC1$11

How this compares

$518 in reported general payments places this provider in the 60th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$31,669
Medicare patients
120
Services billed
388

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XifaxanRifaximin24$72,118
EliquisApixaban70$64,477
OzempicSemaglutide57$62,308
JardianceEmpagliflozin55$47,082
Repatha SyringeEvolocumab59$34,118
XareltoRivaroxaban24$20,531
Atorvastatin Calcium586$9,461
Breo ElliptaFluticasone/Vilanterol13$7,502
Combivent RespimatIpratropium/Albuterol Sulfate12$6,090
Repatha SureclickEvolocumab11$5,741
Fluticasone-SalmeterolFluticasone Propion/Salmeterol39$5,303
Levothyroxine Sodium288$4,861
Atrovent HfaIpratropium Bromide11$4,789
Fluticasone Propionate HfaFluticasone Propionate11$4,647
Losartan Potassium226$4,634

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$45$64,47770 claims
Novo NordiskOzempic$52$62,30857 claims
Boehringer IngelheimJardiance, Combivent Respimat$27$53,17267 claims
Johnson & JohnsonXarelto$41$20,53124 claims
GSKBreo Ellipta$15$7,50213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Clymer

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →